SG/CALL/ABBOTT LABORATORIES/105/0.1/21.06.24 Stock

Warrant

DE000SQ09GB9

Market Closed - Deutsche Boerse AG 03:49:08 2024-05-23 pm EDT
0.21 EUR -4.55% Intraday chart for SG/CALL/ABBOTT LABORATORIES/105/0.1/21.06.24
Current month-47.62%
1 month-57.69%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes
Date Price Change
24-05-23 0.21 -4.55%
24-05-22 0.22 +46.67%
24-05-21 0.15 -11.76%
24-05-20 0.17 -15.00%
24-05-17 0.2 -16.67%

Delayed Quote Deutsche Boerse AG

Last update May 23, 2024 at 03:49 pm EDT

More quotes

Static data

Product typePlain-Vanilla-Warrants
Buy / SellCALL
Underlying ABBOTT LABORATORIES
IssuerLogo Issuer Société Générale Société Générale
WKN SQ09GB
ISINDE000SQ09GB9
Date issued 2022-09-30
Strike 105 $
Maturity 2024-06-21 (29 Days)
Parity 10 : 1
Emission price 1.49
Emission volume N/A
Settlement cash
Currency EUR

Technical Indicators

Highest since issue 2.15
Lowest since issue 0.12
Spread 0.01
Spread %5.00%

Company Profile

Abbott Laboratories specializes in the research, development, manufacturing and marketing of pharmaceutical and medical products. Net sales break down by family of products as follows: - diagnostic systems and instruments (39.1%); - vascular devices (24.7%): endoprosthetic systems, dilation catheters, arterial closures, etc.; - nutrition products (12.1%): pediatric nutrition products, nutritional supplements, and dietetic products; - medicine (8.2%): anesthetics, antiviral products, antibiotics, inhibitors, anti-inflammatories, etc.; - other (15.9%). Net sales are distributed geographically as follows: the United States (38.5%), Germany (5.8%), China (5.6%), India (4.4%), Switzerland (4.1%), Japan (3.8%), Netherlands (2.7%) and others (35.1%).
Sector
-
More about the company

Ratings for Abbott Laboratories

Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings

Consensus: Abbott Laboratories

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
23
Last Close Price
104.8 USD
Average target price
125.7 USD
Spread / Average Target
+19.91%
Consensus